BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8076594)

  • 1. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
    Kook YH; Adamski J; Zelent A; Ossowski L
    EMBO J; 1994 Sep; 13(17):3983-91. PubMed ID: 8076594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
    Yu W; Kim J; Ossowski L
    J Cell Biol; 1997 May; 137(3):767-77. PubMed ID: 9151680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice.
    Lyu MA; Choi YK; Park BN; Kim BJ; Park IK; Hyun BH; Kook YH
    Int J Cancer; 1998 Jul; 77(2):257-63. PubMed ID: 9650562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
    Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS
    Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA.
    Mohanam S; Chintala SK; Mohan PM; Sawaya R; Lagos GK; Gokaslan ZL; Kouraklis GP; Rao JS
    Int J Oncol; 1998 Dec; 13(6):1285-90. PubMed ID: 9824646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    Ossowski L; Clunie G; Masucci MT; Blasi F
    J Cell Biol; 1991 Nov; 115(4):1107-12. PubMed ID: 1659573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma].
    Liao J; Xu S; Tang H; Lian F; Zhu Y
    Zhonghua Bing Li Xue Za Zhi; 2001 Oct; 30(5):357-60. PubMed ID: 11769733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
    Testa JE
    Cancer Res; 1992 Oct; 52(20):5597-603. PubMed ID: 1327511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
    Wang Y; Liang X; Wu S; Murrell GA; Doe WF
    Int J Cancer; 2001 Apr; 92(2):257-62. PubMed ID: 11291054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S; Jasti SL; Kondraganti SR; Chandrasekar N; Kin Y; Fuller GN; Lakka SS; Kyritsis AP; Dinh DH; Olivero WC; Gujrati M; Yung WK; Rao JS
    Clin Cancer Res; 2001 Aug; 7(8):2519-26. PubMed ID: 11489835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
    Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
    Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
    Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
    Br J Cancer; 2003 Jul; 89(2):374-84. PubMed ID: 12865932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
    Mohanam S; Gladson CL; Rao CN; Rao JS
    Front Biosci; 1999 Feb; 4():D178-87. PubMed ID: 9989951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
    Ossowski L
    Cancer Res; 1992 Dec; 52(24):6754-60. PubMed ID: 1333882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
    Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.